The company encounters challenges in raw materials, excipients, analytical testing technology, and product stability in manufacturing its mRNA product candidates. Changes in formulation and manufacturing processes have necessitated, and may continue to necessitate, resupply of batches for preclinical, clinical, or commercial use due to insufficient product stability. The complexity of mRNA production and scaling manufacturing processes can affect clinical and commercial supply. The company relies on various equipment providers and has developed custom manufacturing equipment, with potential risks of malfunction that could delay supply. There is also a risk of cross-contamination in manufacturing facilities, contract research organizations (CROs), external contract manufacturing organizations (CMOs), suppliers, or clinics, particularly given the small scale of some programs. The company plans continuous improvements in manufacturing yield, purity, and pharmaceutical properties as production scales up.
Biontech Se's Comment on Supply Chain
The company encounters challenges in raw materials, excipients, analytical testing technology, and product stability in manufacturing its mRNA product candidates. Changes in formulation and manufacturing processes have necessitated, and may continue to necessitate, resupply of batches for preclinical, clinical, or commercial use due to insufficient product stability. The complexity of mRNA production and scaling manufacturing processes can affect clinical and commercial supply. The company relies on various equipment providers and has developed custom manufacturing equipment, with potential risks of malfunction that could delay supply. There is also a risk of cross-contamination in manufacturing facilities, contract research organizations (CROs), external contract manufacturing organizations (CMOs), suppliers, or clinics, particularly given the small scale of some programs. The company plans continuous improvements in manufacturing yield, purity, and pharmaceutical properties as production scales up.
Sources:
Biontech Se's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Biontech Se’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
